Brief: Medesis Pharma: ANSM Refuses To Authorise Clinical Study Of NanoManganese In COVID-19

Medesis Pharma SA

26/08/2021 16:58

Aug 26 (Reuters) - MEDESIS PHARMA SA  ALMDP.PA :
    * WAS INFORMED BY ANSM ON REFUSAL TO AUTHORIZE CLINICAL
STUDY OF
ITS NANOMANGANESE
    * STUDY OF NANOMANGANESE WAS SUPPOSED TO INVESTIGATE
TREATMENT OF
SEVERE FORMS OF COVID-19
    * HUNGARIAN AUTHORITIES, WHERE APPLICATION WAS MADE IN MAY,
ALSO
REFUSED AUTHORIZATION
    * REFUSALS ARE MOTIVATED BY LACK OF DATA ON PHARMACOKINETICS
    * DECIDED TO REPOSITION ITS COVID-19 CLINICAL DEVELOPMENT
PROGRAMME ON NON-EU COUNTRIES

Source text for Eikon:  ID:nNDL28lR6p 
Further company coverage:  ALMDP.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))